Overview


Anxiety disorders and depression are two of the most common psychiatric disorders that affect a large number of people around the world. Depression is a condition that affects emotions and can also impact the thoughts, actions, and sleeping patterns of the person. Nearly 350 million people suffer from depression. Anxiety is a stress response. Anxiety disorders can include panic disorder, anxiety disorder, obsessive-compulsive disorder, panic disorder, and post-traumatic stress disorder. Anxiety and depression are two of the most common psychological conditions that affect a large number of people around the world. Depression can be linked to an emotional state that further affects one's actions, thoughts, and sleeping patterns. Depression, a brain-related psychiatric condition, can cause you to feel depressed, and tired, lose motivation, and have trouble enjoying your daily routine activities. Depression is primarily caused by stress and social isolation. Anxiety can be helpful in some cases, and it is a natural reaction to stress. Although anxiety disorders and depression are different, people with depression often experience symptoms like nervousness, irritability, and sleeping problems. Anxiety can affect daily tasks, such as schoolwork, relationships, and job performance. Anxiety disorders can range from anxiety or natural nervousness to extreme fear and anxiety. Anxiety disorders such as phobias, obsessive-compulsive disorder, panic disorder, and post-traumatic stress-based disorder are associated with high anxiety rates. It is normal to experience occasional anxiety. Anxiety disorders can cause excessive, persistent, and severe worry and fear in everyday life. Anxiety disorders can often be described as a series of panic attacks, which are sudden episodes of extreme anxiety and fear that escalate quickly to a point.
This market is growing due to the increasing prevalence of anxiety and depression disorders, a declining geriatric population, lower side effects, greater efficacy of novel/innovative medications, and a rising number of drug-resistant mental disorders. The market growth for anxiety disorders and depression is being hampered by the lack of patents for most of the drugs, the dry pipeline for novel drugs, the growing number of generic drugs, and the increasing number of mental disorders that are resistant to drugs. Potential opportunities exist for key players due to innovations and improvements in herbal remedies, as well as a better distribution network.
The personalized therapies and devices market is expected to grow the fastest due to the growing acceptance by healthcare professionals. They have fewer side effects than drugs, which makes them more appealing to patients.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Anxiety Disorders and Depression Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Anxiety Disorders and Depression Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

• Eli Lilly and Company
• Forest Laboratories Inc
• StraZeneca PLC
• Sanofi-Aventis
• MerckCo.
• Pfizer Inc
• GlaxoSmithKline Plc
• Johnson
Johnson
(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class
• SSRIs (Selective Serotonin Reuptake Inhibitors)
• SNRIs (Serotonin- Norepinephrine Reputake Inhibitors)
• TeCAs(Tricyclic Antidepressants)
• MAOIs (Monoamine Oxidase Inhibitors)
• Atypitcal Antipsychotics
• Benzodiazepines
• Anticonvulsants
• Beta-Blockers
• Others
By Pipeline Analysis
• Briintellix (Vortioxetine - Lu AA21004)
• ALKS-5461
• Brexpiprazole (OPC-34712)
By Region
• North America
• Europe
• Asia-Pacific
Latin America
• Middle East and Africa

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

• To provide with an exhaustive analysis on the Anxiety Disorders and Depression Treatment Market By Drug Class, By Pipeline Analysis and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anxiety Disorders and Depression Treatment Market Variables, Trends
    • Scope
        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Drug Class Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances
  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anxiety Disorders and Depression Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anxiety Disorders and Depression Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Drug Class Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Drug Class Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anxiety Disorders and Depression Treatment Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. SSRIs (Selective Serotonin Reuptake Inhibitors)
        2. SNRIs (Serotonin- Norepinephrine Reputake Inhibitors)
        3. TeCAs(Tricyclic Antidepressants)
        4. MAOIs (Monoamine Oxidase Inhibitors)
        5. Atypitcal Antipsychotics
        6. Benzodiazepines
        7. Anticonvulsants
        8. Beta-Blockers
        9. Others
  • 8.   Anxiety Disorders and Depression Treatment Market, By Pipeline Analysis Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Briintellix (Vortioxetine - Lu AA21004)
        2. ALKS-5461
        3. Brexpiprazole (OPC-34712)
  • 9.   North America Anxiety Disorders and Depression Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
           2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2022-2028
  • 10.   Latin America Anxiety Disorders and Depression Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2022-2028
  • 11.   Europe Anxiety Disorders and Depression Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Germany
          2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2022-2028
  • 12.   Asia Pacific Anxiety Disorders and Depression Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
  • 13.   Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2022-2028
  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Eli Lilly and Company
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Forest Laboratories Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. StraZeneca PLC
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Sanofi-Aventis
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Merck Co.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. GlaxoSmithKline Plc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Johnson & Johnson
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients